Experimental Ebola Treatment ZMapp to Enter Human Testing
This article is for subscribers only.
Mapp Biopharmaceutical Inc.’s Ebola drug will soon enter human trials in the U.S. and Liberia following successful efforts to boost production capacity, U.S. health officials said.
Early-stage human trials of ZMapp, which may have helped patients such as American aid worker Kent Brantly survive Ebola, will begin within the next three weeks, according to Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases. The U.S. Biomedical Advanced Research and Development Authority has helped Kentucky BioProcessing LLC, a unit of Reynolds American Inc., to produce enough of the drug for the trials, said BARDA Director Robin Robinson.